Status:
COMPLETED
Inhaled Corticosteroid Treatment of COVID19 Patients With Pneumonia
Lead Sponsor:
Sara Varea
Conditions:
Coronavirus Infection
Eligibility:
All Genders
18-79 years
Phase:
PHASE4
Brief Summary
Randomized, prospective, controlled open label clinical trial aimed at investigating if the addition of inhaled corticosteroids (budesonide) reduces treatment failure (defined as a composite variable ...
Eligibility Criteria
Inclusion
- COVID19 positive
- hospitalized because of pneumonia (status #3 - #4 World Health Organization (WHO) scale)
- without contraindications to receive study treatment
- informed consent
Exclusion
- receiving corticoids (inhaled or systemic)
- receiving anti Interleukin-1 (IL-1) or anti-IL-6 drugs
- receiving high flow oxygen therapy
- receiving mechanical ventilation
- pregnancy
- participating in another intervention trial for COVID19
Key Trial Info
Start Date :
April 21 2020
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
June 30 2021
Estimated Enrollment :
120 Patients enrolled
Trial Details
Trial ID
NCT04355637
Start Date
April 21 2020
End Date
June 30 2021
Last Update
September 22 2021
Active Locations (14)
Enter a location and click search to find clinical trials sorted by distance.
1
Hospital de Infecciosas "Francisco Javier Muñiz"
Ciudad Autonoma de Buenos Aires, Buenos Aires, Argentina, C1282AEN
2
CEMIC (Centro de Educación Médica e Investigaciones Clínicas "Norberto Quirno")
Ciudad Autonoma de Buenos Aires, Buenos Aires, Argentina, C1425DQK
3
Hospital de Rehabilitación Respiratoria "María Ferrer"
Ciudad Autónoma de Buenos Aires, Buenos Aires, Argentina, C1272AAA
4
Hospital Donación "Francisco Santojanni"
Ciudad Autónoma de Buenos Aires, Buenos Aires, Argentina, C1408INH